CASP3 and neoplasm: Casp3/7 inhibition, when combined with cytotoxic or targeted chemotherapies, may therefore serve as a broadly useful strategy for activating therapeutic anti-tumor immunity or potentiating the activity of complementary immunotherapeutic strategies like checkpoint inhibition.